FDA approves Pfizer/BioNTech and Moderna’s adapted COVID-19 vaccines

The US Food and Drug Administration (FDA) has granted approval for Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines, to tackle currently circulating variants.

As previously recommended by the FDA, both vaccines have been adapted to closely target the XBB.1.5. Omicron variant by including a monovalent component.

Both companies’ mRNA vaccines are approved for use in individuals aged 12 years and older and authorised for emergency use in those aged six months to 11 years.

The FDA has said that it is "confident in the safety and effectiveness" of the two updated vaccines and that its risk assessment demonstrated that the benefits of both vaccines for individuals aged six months and older outweighed the risks.

"The public can be assured that these updated vaccines have met the agency’s rigorous scientific standards for safety, effectiveness, and manufacturing quality," said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.

The approvals follow the World Health Organization’s announcement, designating the E.G.5 strain as a ‘variant of interest’, which both Pfizer/BioNTech and Moderna’s updated vaccines responded strongly to.

The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is set to meet to discuss who should receive an updated vaccine.

Albert Bourla, chairman and chief executive officer at Pfizer, said: "We expect this season’s vaccine to be available in the coming days… to prevent severe disease later, when respiratory viruses are at their peak."

"With [the] decision, an updated vaccine will shortly become available that helps address multiple Omicron XBB-related sublineages, which currently account for the vast majority of COVID-19 cases globally," said Professor Ugur Sahin, chief executive officer and co-founder of BioNTech.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!